EAU 2022: ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix With or Without Apalutamide Prior to Radical Prostatectomy for High-Risk Prostate Cancer

EAU 2022 ARNEO trial, the results of ARNEO, a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk

Read the full article here

Related Articles